 | • レポートコード：MRC2202A110 • 出版社/出版日：Mordor Intelligence / 2022年1月28日 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Team User | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の基礎インスリン（長時間作用型インスリン）市場規模が2019年114億ドルに達し、2019年から2024年まで年平均8.2％成長すると予測しています。本調査レポートでは、基礎インスリン（長時間作用型インスリン）の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別（ランタス、レベミール、トウジョ、トレシバ、バサグラー）分析、地域別（北米、ヨーロッパ、中南米、アジア太平洋、中東・アフリカ）分析、競争状況、市場機会・将来傾向などを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の基礎インスリン（長時間作用型インスリン）市場規模：製品種類別（ランタス、レベミール、トウジョ、トレシバ、バサグラー） ・世界の基礎インスリン（長時間作用型インスリン）市場規模：地域別（北米、ヨーロッパ、中南米、アジア太平洋、中東・アフリカ） ・市場指標 ・競争状況（Novo Nordisk AS、Sanofi Aventis、Eli Lilly、Biocon、Julphar、Exir、SEDICO、Wockhardt） ・市場機会・将来傾向 |
The global basal insulin market is expected to register a CAGR of 8.2% during the forecast period of 2019–2024, the market is estimated to reach USD 11.4 billion by 2019.
Key Highlights
- Diabetes is generally considered as a lifestyle disease. Over time, incidences of the disease have increased, with the increase in population around the world.
- Approximately, 100 million people around the world need insulin, including all the people living with Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
- Basal insulin is the most widely used insulin among diabetic patients because of its long-acting effect. Lantus tops the market, and the segment had more than 50% market share in 2017. Many countries have come up with the biosimilars of insulin since 2015.
- Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle to prevent complications.
Key Market Trends
Insulin Glargine Market Access has Widened
- Lantus (insulin glargine) is the first long-acting insulin brought into the market by Sanofi. The product was approved for medical use in the United States in 2000.
- Lantus’ reach was high among patients across different geographical regions, and it is one of the most top-selling drugs for Sanofi, which is exported to more than 100 countries.
- As of 2015, Lantus market share was around USD 7 billion. However, patent protection for Lantus expired in most countries in 2015. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the United States) and Abasaglar (as a biosimilar in the European Union).
- In 2015, Sanofi launched the extended version of Lantus as Toujeo with 300U/mL strength.
- In less stringent regulatory environments, such as India, China, Mexico, and Peru, several biosimilar insulin already exist at lower prices. In India, a glargine biosimilar was first introduced by Biocon in 2011 at a cost that was 40% lower than Lantus. More recently, Lupin Ltd, in agreement with LG Life Sciences, launched its biosimilar ‘Basugine’ in 2014.
- In China, follow-on biologics Basalin (Gan and Lee Pharmaceuticals, Beijing) ranked second in the Chinese glargine market, and occupied a 40% share, after Lantus, in 2017.
The United States Leads the Global Basal Insulin Market
- In the global basal insulin market, the United States held 65.6% market share in 2017. Lantus is the top-selling drug in the country and occupies 49% market share, followed by Levemir, Tresiba, Toujeo, and Basaglar.
- The sale of Lantus is expected to decrease during the forecast period, due to the presence biosimilars Basaglar and Toujeo (which are the extended versions of Lantus).
- The other biosimilar of Lantus (insulin glargine) is Lusduna from Merck, which was tentatively approved by the FDA in the United States. However, despite a favorable nod from the FDA, Merck decided to discontinue Lusduna because of “anticipated pricing and cost of production”.
- Tresiba, launched by Novo Nordisk in 2016, received encouraging feedback from the patients and is expected to show tremendous growth during the forecast period (2019-2024) due to its ultra-long-acting effect. The levemir segment is decreasing due to the switch of patients to Tresiba.
Competitive Landscape
- The global basal insulin market is consolidated, with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers.
- Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).
- Biocon collaborated with Mylan to develop Semglee (insulin glargine biosimilar).
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.1.1.1 Lantus
5.1.1.2 Levemir
5.1.1.3 Toujeo
5.1.1.4 Tresiba
5.1.1.5 Basaglar
5.1.1.6 Insulin Glargine Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk AS
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Julphar
7.1.6 Exir
7.1.7 SEDICO
7.1.8 Wockhardt
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS